Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | IKBKB | O14920 | 3/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501887 | 0.87 | PDPK1 (0.38) | CCNE1CDK2ALDH1A1POLB | |
| SCHEMBL3501617 | 0.81 | GRM2 (0.38) | RAB9ACCNE1CDK2ALDH1A1MAPT | |
| SCHEMBL3498258 | 0.81 | LRRK2 (0.40) | RAB9ACDC7ALDH1A1GAAKDM4E | |
| SCHEMBL3499091 | 0.77 | ALDH1A1 (0.50) | CYP1A2RAB9AALDH1A1GAAPOLB | |
| SCHEMBL13256166 | 0.76 | ALDH1A1 (0.53) | CYP1A2RAB9ACCNE1CDK2ALDH1A1 | |
| SCHEMBL5577976 | 0.74 | CYP1A2 (0.36) | CYP1A2RAB9ACDK2ALDH1A1POLB | |
| SCHEMBL4752790 | 0.73 | ILK (0.32) | — | |
| SCHEMBL5578040 | 0.72 | DYRK1A (0.32) | — | |
| SCHEMBL12127937 | 0.72 | ALDH1A1 (0.56) | CYP1A2RAB9ACDC7CCNE1CDK2 | |
| SCHEMBL13256180 | 0.72 | XIAP (0.51) | CYP1A2RAB9AALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1713814-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | STRUCTURAL GENOMIX (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005068473-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | MAP3K20, MAP4K2, MAP4K3 | CYP1A2 4056/4885RAB9A 1601/4885CDC7 316/4885 |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | MAP3K20, MAP4K2, MAP4K3 | CYP1A2 4056/4885RAB9A 1601/4885CDC7 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.